SCHEDULE 13D/A: Major Shareholder Apeiron Investment Group Increases Stake in ATAI Life Sciences, Secures Board Representation and Voting Rights

Sentiment:

Amendment to Schedule 13D 4 June 2025 9:38 PM

Apeiron Investment Group and its affiliates have increased their beneficial ownership in ATAI Life Sciences N.V. to 22.2%, securing significant voting rights, board representation, and registration rights through new agreements.

Capital raiseThe Issuer issued 9,993,341 Common Shares on June 3, 2025, in connection with an investment by two private investors (PIPE Investors).A Registration Rights Agreement was entered into with Apeiron, Mr. Angermayer, and the PIPE Investors, providing for the resale of their Common Shares, requiring the Issuer to file a registration statement.Apeiron will have customary demand rights for registration statements, and the Issuer has agreed to assist in block trades and marketed or non-marketed underwritten shelf takedown offerings for sales by Apeiron with an aggregate offering price of at least $25 million.

Summary

Apeiron Investment Group Ltd. and its affiliates now collectively beneficially own 46,749,092 Common Shares of ATAI Life Sciences N.V., representing approximately 22.2% of the outstanding shares.
This includes 46,521,717 shares held by Apeiron and its controlled entities, and an additional 227,375 shares held solely by Christian Angermayer.
The total outstanding Common Shares as of June 3, 2025, is 210,330,950, which includes 9,993,341 shares issued on June 3, 2025, to two private investors (PIPE Investors).
New agreements were entered into on June 2, 2025, including a Voting Agreement, Shareholders Rights Agreement, Lock-Up Agreement, and Registration Rights Agreement.
Under the Shareholders Rights Agreement, Apeiron can select two director designees if their beneficial ownership remains above 12.5%, or one designee if between 7.5% and 12.5%.
Apeiron has agreed to a lock-up period for its equity securities, with restrictions gradually falling away over 12 months after the initial period.
The Registration Rights Agreement provides Apeiron and other holders with rights to register their shares for resale, including demand rights and piggyback rights, with the Issuer bearing registration expenses.
Christian Angermayer was granted new options to purchase 630,186 ordinary shares, with vesting tied to a standard four-year schedule and asset value goals by December 31, 2026.

Sentiment

Score: 8

Explanation: The filing indicates strong, continued commitment from a major investor group, securing board representation and facilitating future liquidity for their holdings. This suggests confidence in the company's long-term prospects and strengthens corporate governance through active shareholder involvement. The option grants to a key individual further align interests.

Positives

Increased significant investor commitment from Apeiron and its affiliates, who now own 22.2% of the company.
Major shareholder (Apeiron) gains board representation rights, which can enhance corporate governance and align investor interests with strategic direction.
Registration rights facilitate future liquidity for major shareholders, potentially making the stock more attractive to institutional investors.
Option grants to Christian Angermayer incentivize his continued service as a consultant and align his interests with the company's performance and asset value goals.

Negatives

The issuance of 9,993,341 Common Shares to PIPE investors on June 3, 2025, represents dilution for existing shareholders.
The lock-up agreement restricts Apeiron's ability to transfer shares for a specified period, potentially limiting their immediate liquidity.

Future Outlook

The Issuer may pursue a transaction to move its legal and tax domicile from the Netherlands and Germany to Delaware. The Issuer is also required to file a registration statement under the Securities Act of 1933 for the resale of registrable securities held by Apeiron, Mr. Angermayer, and PIPE Investors, and use reasonable best efforts to cause such registration statement to be declared effective and thereafter keep it effective for specified periods.

Industry Context

This filing primarily details changes in beneficial ownership and related agreements for a specific company, ATAI Life Sciences N.V., rather than providing broad industry trends. ATAI operates in the life sciences sector, specifically focusing on psychedelic and other mental health treatments.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Voting Agreement	Apeiron agreed to vote all its Common Shares in favor of certain matters, including shareholder approvals for the Beckley Psytech Limited acquisition and, subject to conditions, a potential move of the Issuer's legal and tax domicile to Delaware.	June 2, 2025	Ensures major shareholder support for key strategic initiatives and potential corporate restructuring.
Shareholders Rights Agreement	Apeiron gains the right to select director designees: two directors if beneficial ownership is no less than 12.5%, or one director if between 7.5% and 12.5%.	June 2, 2025	Provides significant board representation to a major investor, enhancing shareholder oversight and alignment with strategic direction.
Lock-Up Agreement	Apeiron agreed not to transfer equity securities of the Issuer for a specified period, with restrictions gradually falling away monthly over 12 months after the initial period.	June 2, 2025	Demonstrates long-term commitment from Apeiron by restricting immediate share sales, but limits short-term liquidity for the investor.
Registration Rights Agreement	Provides Apeiron, Mr. Angermayer, and PIPE Investors with rights to register their Common Shares for resale, including demand and piggyback rights, with the Issuer bearing registration expenses.	June 2, 2025	Facilitates future liquidity for major shareholders, potentially making the stock more attractive to institutional investors, but could lead to future share overhang.

Related Party Transactions

Voting Agreement, Shareholders Rights Agreement, Lock-Up Agreement, and Registration Rights Agreement entered into between the Issuer and Apeiron (a controlling shareholder of which is Christian Angermayer, also a reporting person).
Grant of options to Christian Angermayer, who is the controlling shareholder of Apeiron and a key consultant to the Issuer.

Stakeholder Impact

Shareholders: Potential dilution from the PIPE investment; enhanced corporate governance through major shareholder board representation; potential future share overhang from registration rights; increased confidence due to major investor commitment.
Management: Increased accountability due to major shareholder board representation; incentivized through option grants (Christian Angermayer).

Next Steps

Issuer to file a registration statement under the Securities Act of 1933 for the resale of registrable securities held by Apeiron, Mr. Angermayer, and PIPE Investors.
Issuer to use reasonable best efforts to cause the registration statement to be declared effective within specified timelines and keep it effective.
Potential transaction to move the legal and tax domicile of the Issuer from the Netherlands and Germany to Delaware.
Additional 13,375 stock options for Christian Angermayer to vest on or about June 9, 2025.
Portion of Christian Angermayer's new options to vest based on Issuer achieving asset value goals by December 31, 2026.

Key Dates

Date	Description
February 24, 2025	Original Schedule 13D filing date.
May 9, 2025	Date as of which 200,337,609 Common Shares were outstanding, as reported by the Issuer in its Form 10-Q.
May 14, 2025	Date of Issuer's Form 10-Q filing.
June 2, 2025	Date of event requiring filing of this Amendment; date of Voting Agreement, Shareholders Rights Agreement, Lock-Up Agreement, Registration Rights Agreement, and Option Grants to Christian Angermayer.
June 3, 2025	Date 9,993,341 Common Shares were issued to PIPE Investors, resulting in 210,330,950 total Common Shares outstanding.
June 4, 2025	Date of this Amendment No. 1 filing.
June 9, 2025	On or about this date, an additional 13,375 stock options for Christian Angermayer will vest and be exercisable.
December 31, 2026	Deadline for the Issuer to achieve asset value goals for a portion of Christian Angermayer's new options to vest.

Keywords

ATAI Life Sciences, SEC filing, Schedule 13D, beneficial ownership, Apeiron Investment Group, Christian Angermayer, common shares, voting agreement, shareholders rights agreement, lock-up agreement, registration rights, PIPE investment, corporate governance, equity stake, biotech, psychedelic medicine

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.